Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.
Skip to main content

Table 2 Antibody concentrations stratified by the clinical classification

From: The seroprevalence and kinetics of IgM and IgG in the progression of COVID-19

 

Clinical Classification

Sum

P value

Mild

Regular

Severe

N

1

34

6

41

–

Age

25

52.5 (39.8, 64.8)

67.0 (55.5,71.5)

60.0 (39.5,67.5)

0.091

Male

0.0%

50.0%

33.3%

51.2%

0.366

Concentration of COVID-19 IgG (AU/ml)

9.1

22.2 (3.9, 89.4)

157.9 (28.8190.7)

30.6 (8.4, 129.4)

0.056

Seroprevalence of COVID-19 IgG

100.0%

70.6%

100.0%

65.9%

0.256

Concentration of COVID-19 IgM (AU/ml)

8.17

27.9 (4.4, 145.6)

29.7 (8.6, 188.6)

25.5 (5.2152.7)

0.677

Seroprevalence of COVID-19 IgM

100.0%

73.5%

83.3%

75.6%

0.742

  1. Seroprevalence was defined as the proportion of patients with positive antibody results in the study
  2. P < 0.05 was considered a significant difference between groups
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us